Journal of Clinical Oncology, Vol 6, 329-337, Copyright © 1988 by American Society of Clinical Oncology

ARTICLES

Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response

K Winkler, G Beron, G Delling, U Heise, H Kabisch, C Purfurst, J Berger, J Ritter, H Jurgens and V Gerein
University Hospital, Hamburg, FRG.

Following observation of the predictive value of the histologic extent of tumor cell destruction after preoperative chemotherapy for metastasis-free survival (MFS) in osteosarcoma, a randomized study was undertaken with the aim of (1) sparing some patients the unpleasant side effects of highly toxic drugs like doxorubicin (DOX) and cisplatin (CPDD) by administering these drugs postoperatively only after poor response with a milder preoperative regimen, and (2) improving the prognosis of patients responding poorly to the initial treatment by use of a salvage chemotherapy postoperatively. The available patients were divided into two groups. Those in the study arm received a preoperative chemotherapy consisting of high-dose methotrexate (HDMTX) and the triple drug combination of bleomycin, cyclophosphamide, and dactinomycin (BCD) and were switched to DOX/CPDD postoperatively in case of poor response. DOX/CPDD was used besides HDMTX for initial treatment in the control arm, and BCD alternatively with CPDD/ifosfamide (IFO) for postoperative salvage treatment. The response rate of the study arm was significantly inferior to the control arm (26% v 60%; P less than .001). The actuarial 4-year MFS rate of poor responders after salvage chemotherapy also was poorest in the study arm (41%); it was unchanged in the control arm (53%) as compared with that of poor responders from the COSS-80 study without salvage chemotherapy (52%). The actuarial 4-year MFS rate of good responders was 73% in the study arm, 79% in the control arm, and not significantly different from that of the COSS-80 study (84%), although postoperative chemotherapy of good responders had been markedly shortened as compared with the COSS- 80 study. The actuarial 4-year MFS rate of the study arm as a whole was inferior to that of the control arm (49% v 68%; P less than .1) and also inferior to the COSS-80 study (68%; P less than .01), indicating a failure of the employed salvage strategy in general and especially of the effort to restrict the use of the very effective but highly toxic drugs DOX and CPDD to patients resistant to a less toxic initial treatment.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. WESOLOWSKI and G. T. BUDD Use of chemotherapy for patients with bone and soft-tissue sarcomas Cleveland Clinic Journal of Medicine, March 1, 2010; 77(Suppl_1): S23 - S26. [Abstract] [Full Text] [PDF]

				P. Picci, M. Mercuri, S. Ferrari, M. Alberghini, A. Briccoli, C. Ferrari, E. Pignotti, and G. Bacci Survival in high-grade osteosarcoma: improvement over 21 years at a single institution Ann. Onc., November 4, 2009; (2009) mdp502v1. [Abstract] [Full Text] [PDF]

				T. Volker, T. Denecke, I. Steffen, D. Misch, S. Schonberger, M. Plotkin, J. Ruf, C. Furth, B. Stover, H. Hautzel, et al. Positron Emission Tomography for Staging of Pediatric Sarcoma Patients: Results of a Prospective Multicenter Trial J. Clin. Oncol., December 1, 2007; 25(34): 5435 - 5441. [Abstract] [Full Text] [PDF]

				K. M. Skubitz and D. R. D'Adamo Sarcoma Mayo Clin. Proc., November 1, 2007; 82(11): 1409 - 1432. [Abstract] [Full Text] [PDF]

				C. L. Schwartz, R. Gorlick, L. Teot, M. Krailo, Z. Chen, A. Goorin, H. E. Grier, M. L. Bernstein, and P. Meyers Multiple Drug Resistance in Osteogenic Sarcoma: INT0133 From the Children's Oncology Group J. Clin. Oncol., May 20, 2007; 25(15): 2057 - 2062. [Abstract] [Full Text] [PDF]

				S. M. Schuetze Chemotherapy in the Management of Osteosarcoma and Ewing's Sarcoma J Natl Compr Canc Netw, April 1, 2007; 5(4): 449 - 455. [Abstract] [PDF]

				L. Kager, A. Zoubek, U. Kastner, B. Kempf-Bielack, J. Potratz, R. Kotz, G. U. Exner, C. Franzius, S. Lang, R. Maas, et al. Skip Metastases in Osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group J. Clin. Oncol., April 1, 2006; 24(10): 1535 - 1541. [Abstract] [Full Text] [PDF]

				A. S. Petrilli, B. de Camargo, V. O. Filho, P. Bruniera, A. L. Brunetto, R. Jesus-Garcia, O. P. Camargo, W. Pena, P. Pericles, A. Davi, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: Prognostic Factors and Impact on Survival J. Clin. Oncol., March 1, 2006; 24(7): 1161 - 1168. [Abstract] [Full Text] [PDF]

				S. Ferrari, S. Smeland, M. Mercuri, F. Bertoni, A. Longhi, P. Ruggieri, T. A. Alvegard, P. Picci, R. Capanna, G. Bernini, et al. Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups J. Clin. Oncol., December 1, 2005; 23(34): 8845 - 8852. [Abstract] [Full Text] [PDF]

				B. Kempf-Bielack, S. S. Bielack, H. Jurgens, D. Branscheid, W. E. Berdel, G. U. Exner, U. Gobel, K. Helmke, G. Jundt, H. Kabisch, et al. Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS) J. Clin. Oncol., January 20, 2005; 23(3): 559 - 568. [Abstract] [Full Text] [PDF]

				M. Kreuter, R. Bieker, S. S. Bielack, T. Auras, H. Buerger, G. Gosheger, H. Jurgens, W. E. Berdel, and R. M. Mesters Prognostic Relevance of Increased Angiogenesis in Osteosarcoma Clin. Cancer Res., December 15, 2004; 10(24): 8531 - 8537. [Abstract] [Full Text] [PDF]

				M. Lindskog, C. Spenger, J. Jarvet, A. Graslund, and P. Kogner Predicting Resistance or Response to Chemotherapy by Proton Magnetic Resonance Spectroscopy in Neuroblastoma J Natl Cancer Inst, October 6, 2004; 96(19): 1457 - 1466. [Abstract] [Full Text] [PDF]

				N. Marina, M. Gebhardt, L. Teot, and R. Gorlick Biology and Therapeutic Advances for Pediatric Osteosarcoma Oncologist, July 1, 2004; 9(4): 422 - 441. [Abstract] [Full Text] [PDF]

				G. Bacci, A. Briccoli, M. Rocca, S. Ferrari, D. Donati, A. Longhi, F. Bertoni, P. Bacchini, S. Giacomini, C. Forni, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide Ann. Onc., July 1, 2003; 14(7): 1126 - 1134. [Abstract] [Full Text] [PDF]

				L. Kager, A. Zoubek, U. Potschger, U. Kastner, S. Flege, B. Kempf-Bielack, D. Branscheid, R. Kotz, M. Salzer-Kuntschik, W. Winkelmann, et al. Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols J. Clin. Oncol., May 15, 2003; 21(10): 2011 - 2018. [Abstract] [Full Text] [PDF]

				A. M. Goorin, D. J. Schwartzentruber, M. Devidas, M. C. Gebhardt, A. G. Ayala, M. B. Harris, L. J. Helman, H. E. Grier, and M. P. Link Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651 J. Clin. Oncol., April 15, 2003; 21(8): 1574 - 1580. [Abstract] [Full Text] [PDF]

				T. Ozaki, S. Flege, M. Kevric, N. Lindner, R. Maas, G. Delling, R. Schwarz, A. R. von Hochstetter, M. Salzer-Kuntschik, W. E. Berdel, et al. Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group J. Clin. Oncol., January 15, 2003; 21(2): 334 - 341. [Abstract] [Full Text] [PDF]

				L. Aung, R. Gorlick, J. H. Healey, W. Shi, H. T. Thaler, N. A. Shorter, A. G. Huvos, and P. A. Meyers Metachronous Skeletal Osteosarcoma in Patients Treated with Adjuvant and Neoadjuvant Chemotherapy for Nonmetastatic Osteosarcoma J. Clin. Oncol., January 15, 2003; 21(2): 342 - 348. [Abstract] [Full Text] [PDF]

				M. A. Bredella, G. R. Caputo, and L. S. Steinbach Value of FDG Positron Emission Tomography in Conjunction with MR Imaging for Evaluating Therapy Response in Patients with Musculoskeletal Sarcomas Am. J. Roentgenol., November 1, 2002; 179(5): 1145 - 1150. [Abstract] [Full Text] [PDF]

				S. S. Bielack, B. Kempf-Bielack, G. Delling, G. U. Exner, S. Flege, K. Helmke, R. Kotz, M. Salzer-Kuntschik, M. Werner, W. Winkelmann, et al. Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols J. Clin. Oncol., February 1, 2002; 20(3): 776 - 790. [Abstract] [Full Text] [PDF]

				C. P. Gibbs Jr., K. Weber, and M. T. Scarborough Malignant Bone Tumors J. Bone Joint Surg. Am., November 1, 2001; 83(11): 1728 - 1745. [Full Text] [PDF]

				W. H. Meyer, C. B. Pratt, C. A. Poquette, B. N. Rao, D. M. Parham, N. M. Marina, A. S. Pappo, H. H. Mahmoud, J. J. Jenkins, J. Harper, et al. Carboplatin/Ifosfamide Window Therapy for Osteosarcoma: Results of the St Jude Children's Research Hospital OS-91 Trial J. Clin. Oncol., January 1, 2001; 19(1): 171 - 182. [Abstract] [Full Text] [PDF]

				G. Bacci, S. Ferrari, F. Bertoni, P. Ruggieri, P. Picci, A. Longhi, R. Casadei, N. Fabbri, C. Forni, M. Versari, et al. Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report J. Clin. Oncol., December 15, 2000; 18(24): 4016 - 4027. [Abstract] [Full Text] [PDF]

				W. W. Winkelmann Type-B-IIIa Hip Rotationplasty: An Alternative Operation for the Treatment of Malignant Tumors of the Femur in Early Childhood J. Bone Joint Surg. Am., June 1, 2000; 82(6): 814 - 814. [Abstract] [Full Text] [PDF]

				M. Kaya, T. Wada, T. Akatsuka, S. Kawaguchi, S. Nagoya, M. Shindoh, F. Higashino, F. Mezawa, F. Okada, and S. Ishii Vascular Endothelial Growth Factor Expression in Untreated Osteosarcoma Is Predictive of Pulmonary Metastasis and Poor Prognosis Clin. Cancer Res., February 1, 2000; 6(2): 572 - 577. [Abstract] [Full Text]

				R. Gorlick, A. G. Huvos, G. Heller, A. Aledo, G. P. Beardsley, J. H. Healey, and P. A. Meyers Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma J. Clin. Oncol., September 1, 1999; 17(9): 2781 - 2781. [Abstract] [Full Text] [PDF]

				C. A.S. Arndt and W. M. Crist Common Musculoskeletal Tumors of Childhood and Adolescence N. Engl. J. Med., July 29, 1999; 341(5): 342 - 352. [Full Text] [PDF]

				S. S. Bielack, B. Kempf-Bielack, U. Heise, D. Schwenzer, and K. Winkler Combined Modality Treatment for Osteosarcoma Occurring as a Second Malignant Disease J. Clin. Oncol., April 1, 1999; 17(4): 1164 - 1164. [Abstract] [Full Text] [PDF]

				T. Koperna, B. Teleky, S. Vogl, R. Windhager, F. Kainberger, K.-D. Schatz, R. Kotz, and P. Polterauer Vascular Reconstruction for Limb Salvage in Sarcoma of the Lower Extremity Arch Surg, October 1, 1996; 131(10): 1103 - 1107. [Abstract] [PDF]

				R. S. Sawin, E. U. Conrad III, J. R. Park, and J. H. T. Waldhausen Preresection Chemotherapy Improves Survival for Children With Askin Tumors Arch Surg, August 1, 1996; 131(8): 877 - 880. [Abstract] [PDF]